Advertisements

Omeprazol Biosan

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Omeprazol Biosan

The following table provides essential facts regarding the identity and classification of Omeprazol Biosan.

Property Description
Active ingredient Omeprazole (a racemic mixture)
Form Delayed-release capsules, Enteric-coated tablets (Oral)
Pharmacological class Proton-Pump Inhibitor (PPI)
General purpose Sustained and powerful suppression of gastric acid secretion
Origin Synthetic organic compound (Benzimidazole derivative)

Defining Omeprazol Biosan: Classification and Origin

Omeprazol Biosan is a medication whose active component, Omeprazole, belongs to the Proton-Pump Inhibitor (PPI) class of drugs, which are potent antisecretory agents. It is a synthetic compound derived from the substituted benzimidazole chemical family, fundamentally designed to reduce the volume of acid produced by the stomach. The function of Omeprazole is based on the irreversible inhibition of the H+/K+-ATPase enzyme system, which is the final step in gastric acid production. This verified mechanism, which is clinically recognized for effective gastric acid control, confirms the drug's specialized expertise in managing acid output.

As a single-ingredient product, or monotherapy, Omeprazol Biosan achieves its therapeutic effect through this singular, powerful mechanism. Unlike older acid reducers, PPIs fundamentally target the final step of acid secretion, offering a sustained and profound suppression of gastric acidity. This classification means the medication is intended for conditions aggravated by excessive acid production, such as those that cause persistent heartburn.

Composition, Physical Form, and Therapeutic Purpose

The core composition of this preparation is the active substance, Omeprazole, which exists as a racemic mixture. Due to the fact that Omeprazole is inherently acid-labile—easily destroyed by stomach acid—Omeprazol Biosan is specifically formulated into specialized oral dosage forms, such as enteric-coated tablets or delayed-release capsules. The formulation is necessary because the active drug must remain intact until it leaves the stomach and is absorbed in the small intestine. This specialized delivery method is a characteristic of all therapeutic Omeprazole products, ensuring its optimal function.

This unique composition, which includes excipients designed for protection, enables the Omeprazole to concentrate in the parietal cells. The ultimate therapeutic purpose linked to this delivery system is the reliable suppression of gastric acid, leading to a sustained elevation of the stomach’s pH. This action is crucial for mitigating irritation and enabling the natural healing process in tissues damaged by acid-related issues.

Regulatory References

  1. Omeprazole (StatPearls/NIH Monograph)
Advertisements

What side effects are possible with Omeprazol Biosan?

Possible side effects and safety information

The safety profile of Omeprazol Biosan, whose active ingredient is omeprazole, is defined by regulatory documents that classify potential adverse reactions based on their frequency and the body system affected.

Frequency-Classified Adverse Reactions

Adverse reactions are organized into official frequency categories:

  • Common events (occurring in 1/100 to 1/10 users) documented in regulatory labels primarily involve gastrointestinal disorders (e.g., abdominal pain, flatulence, diarrhea, constipation) and headache.
  • Uncommon reactions (occurring in 1/1,000 to 1/100 users) include dizziness, somnolence, insomnia, and increases in liver enzymes.
  • Rare events (occurring in 1/10,000 to 1/1,000 users) may affect the blood (e.g., leukopenia, thrombocytopenia) or the immune system (e.g., hypersensitivity reactions).

Serious and Exposure-Related Safety Concerns

The official label highlights specific rare but clinically significant adverse reactions and safety patterns linked to duration of use.

  • Serious Adverse Reactions officially noted include severe cutaneous adverse reactions (such as Stevens-Johnson Syndrome), acute tubulointerstitial nephritis, and hepatic failure in patients with pre-existing severe liver disease.
  • Long-Term Exposure: Use for a year or longer is associated with an increased regulatory risk of bone fractures (hip, wrist, or spine) and hypomagnesemia (low serum magnesium levels). Furthermore, Vitamin B-12 deficiency has been reported with prolonged daily treatment.

Population Notes and Safety Restrictions

Caution is noted for patients with hepatic impairment due to increased exposure to the drug. The label emphasizes that symptomatic improvement does not rule out the presence of a gastric malignancy. Additionally, PPI therapy may be associated with an increased risk of developing Clostridium difficile-associated diarrhea.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Acute overdose with Omeprazol Biosan is generally described in official regulatory documents as a condition that is typically well-tolerated, with serious consequences being rare. Even with the ingestion of very high single doses, the observed effects are usually reversible, and regulatory reports indicate no serious outcomes have been documented in connection with large single overdoses.

Documented Clinical Presentation

The officially reported clinical signs and symptoms of overdose primarily involve the gastrointestinal and central nervous systems. Documented manifestations frequently include abdominal pain, nausea, vomiting, diarrhea, and flatulence. Central nervous system effects such as headache, lethargy, dizziness, and confusion have also been noted in clinical experience. Tachycardia (rapid heart rate) is among the reported cardiovascular effects.

Mandated Emergency Action

Despite the low severity profile, government regulatory guidance mandates that immediate medical attention must be sought for all suspected overdoses. Users are instructed to contact a hospital emergency department or a poison control center immediately for guidance. As no specific antidote is known for Omeprazol Biosan, the official management approach is strictly symptomatic and supportive, involving general supportive measures and close clinical observation.

Advertisements

Therapeutic Uses of Omeprazol Biosan

Understanding Omeprazol Biosan

Omeprazol Biosan is a medication classified as a proton pump inhibitor (PPI). Its primary function is to reduce the volume of acid produced in the stomach. By regulating gastric acid secretion, it allows the lining of the esophagus and stomach to heal and prevents further irritation caused by excessive acidity.

Main Therapeutic Uses

This medication is used to manage several conditions related to gastric acid imbalance:

  • Gastroesophageal Reflux Disease (GERD): It is used to treat symptoms of acid reflux, such as heartburn and acid regurgitation, which occur when stomach acid flows back into the esophagus.
  • Gastric and Duodenal Ulcers: It aids in the healing of ulcers located in the stomach or the upper part of the small intestine.
  • Zollinger-Ellison Syndrome: It is utilized in the management of rare conditions where the stomach produces extreme amounts of acid due to certain growths.
  • Erosive Esophagitis: It helps repair damage to the esophagus caused by chronic exposure to stomach acid.

Benefits of Treatment

The primary benefit of using Omeprazol Biosan is the stabilization of the internal gastric environment. By maintaining lower acid levels, the medication provides the following clinical advantages:

  • Symptom Relief: It reduces the frequency and severity of discomfort associated with hyperacidity.
  • Tissue Recovery: It creates an environment conducive to the natural healing of mucosal linings that have been damaged by acid.
  • Prevention of Recurrence: For patients with chronic acid issues, consistent regulation of acid production can help prevent the return of ulcers or inflammation.
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Omeprazol Biosan

Eligibility to use Omeprazol Biosan is defined by official regulatory documents based on patient population, concurrent medication use, and specific medical conditions.

Contraindicated Populations (Must Not Use)

The medicine is contraindicated for patients with a known hypersensitivity to the active ingredient, omeprazole, other substituted benzimidazoles, or any component of the formulation. It is also prohibited for concomitant use with rilpivirine-containing products.

Age and Condition Eligibility

Population Group Regulatory Eligibility Status
Adults and Adolescents Approved for all indications.
Children ge 1 Year Old Approved for symptomatic GERD and healing of Erosive Esophagitis.
Infants < 1 Month Old Safety and efficacy have not been established.
Impaired Hepatic Function Use is restricted; dose reduction should be considered.
Impaired Renal Function Dose adjustment is not needed.

Other Restrictions

Before initiating treatment for a gastric ulcer, the presence of gastric malignancy must be excluded, as the medication may alleviate symptoms and delay diagnosis. Omeprazole is excreted into human milk, and use is generally not recommended while breastfeeding. Use during pregnancy is considered, with risks deemed unlikely, but is generally permitted only if the benefit outweighs the potential risk.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Omeprazole can alter the effects of numerous other medicines through two primary mechanisms: increasing gastric pH and inhibiting the enzyme CYP2C19. These interactions require specific regulatory constraints on co-administration.

Clinical Interaction Constraints

Interacting Medicine Category Constraint/Regulatory Note
Antiretrovirals (e.g., Atazanavir, Nelfinavir, Rilpivirine) Concomitant use is not recommended or contraindicated due to significantly reduced plasma concentrations of the antiretroviral.
Antiplatelet agents (e.g., Clopidogrel) Concomitant use should be avoided as omeprazole diminishes the formation of the active metabolite, reducing anti-platelet activity.
Anticoagulants (e.g., Warfarin) and Phenytoin Close monitoring (e.g., of INR/Prothrombin Time) is required, as omeprazole can prolong elimination, potentially increasing plasma levels and the risk of toxicity.
Immunosuppressants (e.g., Tacrolimus, Cyclosporine) Monitoring of serum levels and potential dose adjustment of the immunosuppressant are required due to increased concentrations.
Digoxin Monitoring for potential toxicity is necessary due to increased absorption resulting from elevated gastric pH.
Methotrexate Patients receiving high-dose Methotrexate should consider temporary omeprazole withdrawal due to elevated Methotrexate levels.
pH-dependent medicines (e.g., Ketoconazole, Iron Salts) Reduced absorption and efficacy of these medicines may occur due to increased gastric pH.
CYP2C19 and/or CYP3A4 Inducers (e.g., Rifampin, St. John's Wort) Concomitant use should be avoided as these agents reduce omeprazole plasma concentrations, leading to decreased efficacy.

These constraints define the official interaction profile, necessitating avoidance, dose adjustments, or heightened monitoring when omeprazole is co-administered with specific drug classes.

Advertisements

Mechanism of Action

Omeprazol Biosan functions through a highly specific pharmacological mechanism centered on the irreversible inhibition of gastric acid production. The active substance, Omeprazole, is chemically a prodrug that requires activation. Omeprazole, a weak base, selectively accumulates within the intensely acidic environment of the secretory canaliculi of the parietal cells. This acidic pH converts the prodrug into its active sulfenamide compound. The active metabolite then targets the final enzyme in the acid-secretion pathway: the gastric H^+/ K^+-ATPase (Proton Pump). It performs an irreversible inhibition by forming a stable covalent bond with specific cysteine residues on the enzyme, permanently disabling the pump. By suppressing the transport of H^+ ions, this action ensures a significant reduction in secretory capacity, regardless of the initial stimulus (histamine, gastrin, or acetylcholine). This mechanism results in a long-lasting elevation of intragastric pH. The duration of this physiological action is a direct consequence of the irreversible nature of the inhibition; the effect persists until the body synthesizes and inserts entirely new H^+/ K^+-ATPase enzymes, typically over sim18 to 24 hours. The sustained reduction in gastric acidity triggers a physiological feedback loop, increasing the secretion of the hormone Gastrin ( hypergastrinemia).

Advertisements

Dosage and Administration Information

Omeprazol Biosan is administered exclusively via the oral route, typically supplied as delayed-release capsules or enteric-coated tablets in strengths of 10 mg, 20 mg, and 40 mg. The formulation is designed to be gastro-resistant, meaning the tablet or capsule must be swallowed whole and must not be crushed or chewed to ensure the medication is protected from stomach acid until it reaches the small intestine for absorption.

Administration is generally once daily, with the dose taken before eating (pre-prandially), preferably in the morning. Standard adult dosing regimens range from 10 mg to 40 mg per day, depending on the specific condition being treated. Use follows defined course durations: short-term treatment for conditions like erosive esophagitis typically lasts 4 to 8 weeks, while long-term continuous use is reserved for conditions such as pathological hypersecretory conditions (PHC).

In PHC, daily doses can be adjusted higher, requiring the dose to be divided and taken two or three times daily when the total daily dose exceeds 80 mg. Regarding specific populations, it is noted that no dose adjustment is required for patients with renal impairment or in older adults. However, a lower daily dose of 10 mg to 20 mg may be sufficient for patients with severe hepatic impairment.

Advertisements

Recent Clinical Evidence

Evidence for Healing Duodenal and Gastric Ulcers

Omeprazol Biosan was evaluated in research exploring conditions such as peptic ulcers. This research has primarily involved short-term Randomized Controlled Trials (RCTs) focusing on adult patients. Researchers examined the rate of endoscopic healing and tracked the resolution of symptoms, such as pain and heartburn. Findings describe patterns observed in these studies where measurements of healing were tracked and compared against placebo groups. However, the research mainly applies only to the initial, short-term healing phase, and long-term outcomes are not well characterized regarding ulcer recurrence once the study follow-up has ended.

Evidence for Managing Acid Reflux Disease (GERD)

Evidence for managing symptomatic Gastroesophageal Reflux Disease (GERD) and Erosive Esophagitis (EE) is derived from RCTs and systematic reviews. Studies monitored changes in symptom severity scores and tracked the endoscopic healing of erosions in the esophagus. Maintenance studies reported measurements of recurrence or relapse rates when the medication was observed continuously. However, the certainty remains low concerning the outcomes of the medication used beyond 12 months, as follow-up durations were limited in the available controlled trials.

Research on H. pylori Eradication and Special Populations

Omeprazol Biosan was evaluated as part of a combination regimen with antibiotics to address Helicobacter pylori infection. Short-term RCTs measured the rate of bacterial eradication and tracked ulcer recurrence rates during the defined post-treatment observation period. These findings were dependent on the specific antibiotics included in the regimen.

Dedicated research has also explored its use in pediatric patients (children and infants as young as 1 year old). For all populations, long-term outcomes are not fully established by controlled clinical trials, and evidence quality varies, with results applying only to the populations studied. Studies focusing on patients with complex comorbid conditions or very young infants remain limited.

Key Studies & References

  1. Omeprazole and H-2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis
  2. Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NICE Guideline NG1)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Omeprazol Biosan (FAQ)

Q: Is Omeprazol Biosan a type of antacid or is it something different?

Omeprazol Biosan is not a traditional antacid. It belongs to a specialized group of medicines called Proton Pump Inhibitors (PPIs). Unlike antacids, which only neutralize acid already present in the stomach, this medication works by stopping the acid production at its source in the stomach lining. This action provides a sustained reduction in the amount of acid produced.

Q: Can I open the capsules of Omeprazol Biosan and mix them with food?

Official administration options exist for patients who may have difficulty swallowing the capsules whole. The contents of the delayed-release capsule can be emptied and mixed with specific types of soft, slightly acidic food, such as applesauce. The mixture must be swallowed immediately without chewing, as the specialized formulation is designed to be protected until absorbed.

Q: What are the most commonly reported side effects of Omeprazol Biosan?

According to official product information, the most commonly reported events are classified as common, meaning they may affect up to 1 in 10 users. These common adverse reactions primarily involve gastrointestinal disorders, such as abdominal pain, flatulence, and diarrhea, as well as headache.

Q: Is Omeprazol Biosan considered a long-term or short-term treatment?

Regulatory documents describe the medication for both short-term use and long-term continuous use, depending on the patient’s condition. Short-term use is common for the initial healing phase of conditions like erosive esophagitis. Long-term continuous use is reserved for specific, chronic conditions like pathological hypersecretory conditions.

Q: Can Omeprazol Biosan be used in conjunction with antacids?

Official drug interaction reports generally do not list a specific constraint or avoidance warning for the co-administration of omeprazole with antacids. Although antacids work through a different, short-acting mechanism compared to omeprazole, they can typically be used together as needed. Information regarding combined use is best reviewed by a healthcare professional.

Q: What is the meaning of 'reversible proton pump inhibitor' in relation to Omeprazol Biosan?

Omeprazol Biosan is classified as an irreversible proton pump inhibitor. This means the active substance permanently disables the acid-producing enzyme system in the stomach. The sustained acid-suppressing effect persists until the body synthesizes new enzyme, which takes about 18 to 24 hours.

Q: Does Omeprazol Biosan affect the absorption of certain vitamins or minerals?

Official warnings note that the use of this drug for a year or longer is associated with regulatory risks concerning the absorption of certain nutrients. Specifically, prolonged use may be associated with an increased regulatory risk of low serum magnesium levels (hypomagnesemia) and Vitamin B-12 deficiency.

Q: Does Omeprazol Biosan start working immediately after I take it?

The onset of the acid-reducing effect begins within approximately one hour after the first dose, with the maximum effect on acid suppression occurring within two hours. The onset of action is not immediate, and the medication is not generally used for on-demand symptom relief.

Q: How long does it typically take to feel the effects of Omeprazol Biosan?

Studies and official consumer information indicate that full symptom relief may take between 1 and 4 days of continuous treatment. Symptomatic improvement may be gradual, and following the duration of use as prescribed is necessary for the intended effect.

Q: Is Omeprazol Biosan available without a prescription in some places?

The active ingredient, omeprazole, is commonly available in both over-the-counter (OTC) forms without a prescription and as a prescription-only medicine. The availability and required method of purchase depend on the specific dosage strength and the regulatory region.

Q: Can Omeprazol Biosan cause headaches or dizziness?

Official safety information documents that headache is classified as a common adverse reaction associated with the use of omeprazole. Dizziness and sleepiness are listed as uncommon adverse reactions.

Q: Are there any specific foods or drinks to avoid while using Omeprazol Biosan?

Official information generally indicates that one can eat as normal while using the drug. However, it is noted that consuming alcohol may stimulate stomach acid production, which could potentially work against the medicine's benefits and worsen the underlying symptoms being treated.

Q: Is it possible for Omeprazol Biosan to interact with common pain relievers like ibuprofen?

Official drug interaction information does not typically list specific interactions that require warnings or monitoring for common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. Specific concerns about combining medications are best addressed by reviewing official guidance with a healthcare professional.

Q: Are there different strengths or formulations of Omeprazol Biosan available?

The product is available in different strengths, typically including 10 mg, 20 mg, and 40 mg. It is also produced in various oral forms, such as delayed-release capsules and delayed-release tablets, which are specifically designed to protect the medicine from stomach acid.

Q: Can Omeprazol Biosan be used for occasional heartburn or is it only for chronic conditions?

Omeprazole is generally indicated for the treatment of frequent heartburn, which is typically defined as occurring two or more days a week. It is officially stated that the medicine is not intended for the relief of infrequent or occasional heartburn symptoms.

Q: Does the time of day I take Omeprazol Biosan affect how well it works?

Regulatory information recommends taking the medicine once daily, preferably in the morning and before a meal. Following the scheduled administration time, which is usually once daily, helps to achieve sustained acid suppression throughout the day, according to regulatory documents.

Q: How long after stopping Omeprazol Biosan might the effects wear off?

Official pharmacodynamic information indicates that when the medication is discontinued, the acid-secretion activity does not return immediately. Instead, acid levels return gradually to baseline over a period of approximately three to five days.

Q: Is Omeprazol Biosan known to cause dry mouth or changes in taste?

Official adverse reaction lists categorize side effects by frequency of occurrence. Specific effects like dry mouth or taste disturbance are not classified among the common or uncommon reported events in the regulatory summaries.

Q: How does Omeprazol Biosan affect the natural balance of bacteria in the gut?

Official safety warnings note that changing the stomach's acid level may affect the natural balance of bacteria. Specifically, PPI therapy is noted to be associated with an increased regulatory risk of developing Clostridium difficile-associated diarrhea.

Q: Is there any research on Omeprazol Biosan use during pregnancy?

Epidemiologic studies have examined the use of omeprazole in pregnant patients. The results from these studies have generally indicated that major malformative risks are considered unlikely with use.

Q: What is the average duration of treatment with Omeprazol Biosan for short-term use?

For the treatment of frequent heartburn, the typical short-term course of treatment is often defined as 14 consecutive days. Longer courses of up to 4 to 8 weeks may be indicated for more severe conditions like erosive esophagitis.

Q: Are there any known issues with alcohol consumption while taking Omeprazol Biosan?

While the drug does not typically interact directly with how the body processes alcohol, official patient advice notes that consuming alcohol can stimulate stomach acid. This may worsen the underlying acid-related symptoms, potentially reducing the drug's therapeutic benefit.

Q: What is the main difference between Omeprazol Biosan and other 'prazoles'?

Omeprazol Biosan, like other medications in the 'prazole' class, is classified as a Proton Pump Inhibitor (PPI). These drugs all share the fundamental action of reducing gastric acid secretion through the irreversible inhibition of the textH^+/ textK^+-ATPase enzyme system.

Q: What are the signs that Omeprazol Biosan is achieving its intended purpose?

In clinical studies, the effectiveness is measured primarily by tracking the resolution of symptoms like heartburn and pain. For conditions like ulcers or esophagitis, signs of effectiveness also include the endoscopic healing of tissue damage caused by acid.

Q: What should I do if I experience an unusual side effect while on Omeprazol Biosan?

Regulatory guidance includes instructions for patients to report any suspected or unusual adverse reactions. Patients should consult with their healthcare provider or report the reaction directly to the national drug authority (such as the FDA or EMA) for monitoring.

Q: Is there a rebound effect of increased stomach acid after stopping Omeprazol Biosan?

Official pharmacodynamic information notes that after discontinuing the drug, the secretory activity of stomach acid returns gradually. The return to baseline levels is not sudden but occurs over a period of approximately three to five days.

Q: How is Omeprazol Biosan used to treat reflux disease?

The drug is officially indicated for the treatment of symptomatic Gastroesophageal Reflux Disease (GERD) and for the healing of Erosive Esophagitis (EE). Its action of suppressing gastric acid helps to mitigate irritation and allows the damaged esophageal tissue to heal.

Q: What is the evidence base for Omeprazol Biosan in treating non-erosive reflux disease?

Omeprazole is officially indicated for the treatment of symptomatic GERD in patients who do not have visible esophageal lesions. This condition is often referred to as non-erosive reflux disease, and treatment is indicated for a defined, short duration.

Q: Can a patient with impaired renal function use Omeprazol Biosan?

Official regulatory guidelines state that patients with impaired kidney function do not require an adjustment to the dose of omeprazole. This information is based on the drug's established metabolic profile.

Q: Does Omeprazol Biosan interact with oral contraceptives?

Official drug interaction reports generally indicate that omeprazole is not expected to reduce the efficacy of combined oral contraceptive pills. However, it is always helpful to inform a healthcare provider of all medications being used.

Advertisements

How should Omeprazol Biosan be stored and disposed of?

Storage and Disposal of Omeprazole (Omeprazol Biosan)

Omeprazole capsules must be stored according to regulatory requirements to preserve the integrity of the specialized acid-labile formulation.

Required Storage Conditions

Condition Requirement
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Do not store above 30 C.
Protection The product must be protected from moisture and light.
Container Keep in the original package (blisters) or tightly closed container (bottles).
Child Safety Must be kept out of the sight and reach of children.

Disposal

For most formulations, disposal of unused or expired Omeprazole must be carried out in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Omeprazol Biosan found in:

A-Z Index: